文献速递前列腺癌

基于多序列MRI纹理分析的前列腺癌异质性评分:活检时检测、分层与病灶选择

Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy.
PubMed 文献 · BJU Int · 2019-02-05

该研究对20例活检时行多参数MRI的患者生成536个影像体积,构建熵评分(ES=E ADC+E Ktrans+E Ve+E T2WI),以系统饱和穿刺联合MRI靶向采样为参考标准,评估ES对临床显著前列腺癌(SPCa)的检测效能,并与视觉评分(VS)比较。结果显示ES与Gleason评分及最大癌核心长度相关,ES阈值16.61 NAT时敏感性和阴性预测值均为100%,且ES预测病灶阳性的比例显著高于VS。

要点

  • ES与Gleason评分(rs=0.568,P=0.033)和最大癌核心长度(ρ=0.781,P<0.001)相关。
  • ES与VS检测SPCa的AUC分别为0.89和0.91,差异无统计学意义(P=0.75)。
  • ES阈值16.61 NAT时敏感性和阴性预测值均为100%,53%的MRI病灶可避免活检。

核心结论

  • 基于多序列MRI的熵评分(ES)在检测和分层临床显著前列腺癌方面表现出高性能。
  • ES在预测病灶阳性方面优于视觉评分,有望用于活检靶点选择。

研究设计与样本

  • 早期概念验证研究,纳入20例连续在活检时接受多参数MRI的患者,生成536个影像体积。
  • 参考标准为系统饱和穿刺联合MRI靶向采样,共422条穿刺芯。

主要发现

  • 20例患者中12例(60%)发现任何癌症(Gleason评分6-8),中位PSA为8.22 ng/mL。
  • SPCa的平均ES为17.96(95%CI 0.72)NAT,显著高于非SPCa的15.33(95%CI 0.76)NAT。
  • ES与Gleason评分相关(rs=0.568,P=0.033),与最大癌核心长度相关(ρ=0.781,P<0.001)。
  • ES和VS检测SPCa的AUC分别为0.89和0.91,差异无统计学意义(P=0.75)。
  • ES阈值16.61 NAT时敏感性100%、阴性预测值100%;ES阈值下SPCa阳性病灶比例54%,显著高于VS的24%(P<0.001)。

关键数值与推荐

  • SPCa定义为单条穿刺芯Gleason评分≥3+4或任何分级癌症长度>3 mm。
  • ES计算公式为E ADC + E Ktrans + E Ve + E T2WI。
  • ES阈值16.61 NAT时敏感性100%、阴性预测值100%。
  • ES阈值下54%的MRI病灶为SPCa阳性,VS(评分3、4、5)为24%,差异显著(P<0.001)。
  • 53%的MRI病灶可避免活检而不遗漏显著疾病。

临床怎么用

  • ES可用于辅助选择活检靶点,减少不必要的穿刺采样。
  • ES阈值16.61 NAT可能作为避免活检的参考指标,但需进一步验证。

局限性

  • 样本量小(20例患者),为早期概念验证研究。
  • ES阈值16.61 NAT为数值估计,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To undertake an early proof-of-concept study on a novel, semi-automated texture-based scoring system in order to enhance the association between magnetic resonance imaging (MRI) lesions and clinically significant prostate cancer (SPCa). PATIENTS AND METHODS: With ethics approval, 536 imaging volumes were generated from 20 consecutive patients who underwent multiparametric MRI (mpMRI) at time of biopsy. Volumes of interest (VOIs) included zonal anatomy segmentation and suspicious MRI lesions for cancer (Likert Scale score >2). Entropy (E), measuring heterogeneity, was computed from VOIs and plotted as a multiparametric score defined as the entropy score (ES) = E ADC + E Ktrans + E Ve + E T2WI. The reference test that was used to define the ground truth comprised systematic saturation biopsies coupled with MRI-targeted sampling. This generated 422 cores in all that were individually labelled and oriented in three-dimensions. Diagnostic accuracy for detection of SPCa, defined as Gleason score ≥3 + 4 or >3 mm of any grade of cancer on a single core, was assessed using receiver operating characteristics, correlation, and descriptive statistics. The proportion of cancerous lesions detected by ES and visual scoring (VS) were statistically compared using the paired McNemar test. RESULTS: Any cancer (Gleason score 6-8) was found in 12 of the 20 (60%) patients, with a median PSA level of 8.22 ng/mL. SPCa (mean [95% confidence interval, CI] ES = 17.96 [0.72] NATural information unit [NAT]) had a significantly higher ES than non-SPCa (mean [95% CI] ES = 15.33 [0.76] NAT). The ES correlated with Gleason score (rs = 0.568, P = 0.033) and maximum cancer core length (ρ = 0.781; P < 0.001). The area under the curve for the ES (0.89) and VS (0.91) were not significantly different (P = 0.75) for the detection of SPCa amongst MRI lesions. Best ES estimated numerical threshold of 16.61 NAT led to a sensitivity of 100% and negative predictive value of 100%. The proportion of MRI lesions that were found to be positive for SPCa using this ES threshold (54%) was significantly higher (P < 0.001) than using the VS (24% of score 3, 4, 5) in a paired analysis using the McNemar test. In all, 53% of MRI lesions would have avoided biopsy sampling without missing significant disease. CONCLUSION: Capturing heterogeneity of prostate cancer across multiple MRI sequences with the ES yielded high performances for the detection and stratification of SPCa. The ES outperformed the VS in predicting positivity of lesions, holding promise in the selection of targets for biopsy and calling for further understanding of this association.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Orczyk C, Villers A, Rusinek H, et al. Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy. BJU Int. 2019. PMID: 30378238. doi:10.1111/bju.14603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。